Ocugen, Inc. (NASDAQ:OCGN) and peers have negative Return on Invested Capital ratios.

From Financial Modeling Prep: 2025-06-20 11:00:00

Ocugen, Inc. (NASDAQ:OCGN) focuses on gene therapies for blindness and vaccines for infectious diseases. Competitors like Bionano Genomics, Zomedica Corp., SNDL Inc., Vaxart, and Senseonics Holdings also offer innovative healthcare solutions.

Ocugen’s Return on Invested Capital (ROIC) is -118.07%, below its Weighted Average Cost of Capital (WACC) of 21.99%, resulting in a -5.37 ROIC to WACC ratio. Bionano Genomics has a -121.64% ROIC against a 5.92% WACC, with a -20.54 ratio. SNDL Inc. is the most efficient with a -8.38% ROIC and 16.49% WACC, yielding a -0.51 ratio.

The analysis reveals that Ocugen and its peers struggle to surpass their cost of capital due to high research and development costs in the biopharmaceutical sector.



Read more at Financial Modeling Prep:: Ocugen, Inc. (NASDAQ:OCGN) Financial Performance A…